EUDA: Powering digital asset adoption in wellness
A demographic wave is reshaping Asia: rapidly aging populations are set to drive multi-trillion-dollar demand for non-invasive, preventive, and longevity-focused healthcare. And one under-the-radar Singapore innovator may be building one of the region’s most comprehensive toolkits—from next-gen nutraceuticals and bioenergy therapies to stem-cell programs and emerging genetic-modulation technologies.
Now, EUDA is adding a new catalyst to this ecosystem: the QB utility token.
​
Rather than functioning as a simple rewards mechanism, the QB token transforms EUDA’s wellness network into a unified, digital-first engagement platform. Customers can earn and redeem QB across EUDA’s full suite of offerings—spanning Bioenergy Capsule sessions, EUDA Helixe supplements, and select stem-cell services—creating a closed-loop loyalty system that deepens retention and expands lifetime value.
​
By combining preventive healthcare with tokenized digital engagement, EUDA is positioning itself at the center of Asia’s longevity boom—where wellness, technology, and consumer incentives converge into a next-generation health ecosystem
Why the Market Set-Up Looks So
Compelling Right Now
Demographic Tailwind – By 2030, more than 550 million people in China and ASEAN will be over 60, driving a longevity market forecast to eclipse $2 trillion annually.
Regulatory Fast-Track – Singapore and Malaysia have introduced expedited pathways for wellness and cell-therapy products, shrinking go-to-market timelines.
Tech Convergence – Advances in CRISPR, stem-cell banking, and AI-driven diagnostics are converging, lowering costs and boosting efficacy—perfect timing for first movers.
EUDA Health Holdings Limited (EUDA)
Ticker / Exchange
EUDA / NASDAQ
Core Focus
Non-invasive, preventive longevity solutions
Headquarters
Singapore
Target Geography
Singapore, Malaysia, India and Mainland China
EUDA’s mission
is simple yet audacious
Transform the health and wellness landscape by leveraging cutting-edge technology to enhance non-invasive treatments and expand holistic healthcare access in Southeast Asia. The company offers a diverse portfolio of innovative non-invasive wellness products and services, including bioenergy capsules and stem cell therapies, marketed under the CK Health brand in Malaysia and Singapore.
EUDA Integrates QB Utility Token into Its Healthcare Ecosystem
EUDA’s integration of the QB utility token marks a major step toward building a unified digital health and rewards ecosystem, letting customers earn and redeem tokens across treatments, supplements, and longevity programs. By anchoring the platform on blockchain infrastructure and interoperability with USD1 stablecoins, EUDA is positioning itself at the forefront of transparent, compliant digital healthcare engagement. This creates a scalable foundation for cross-border wellness experiences that blend preventive care, tokenized incentives, and seamless digital access across Asia.
1
Tangible connection between crypto and product
The token integration is not a speculative crypto play; EUDA only receives QB tokens in exchange for products and services, keeping transactions non-monetary and reducing balance sheet exposure while still capturing ecosystem value.
2
Built for customer retention
The digital rewards architecture strengthens customer retention and lifetime value across high-margin wellness and longevity services, creating a scalable pathway for recurring revenues and cross-market expansion.
3
Partnership with QB issuer
Partnering with QB Limited allows EUDA to leverage an independently developed, purpose-built token and established distribution channels in Hong Kong and Macau, accelerating digital engagement without incurring full infrastructure, regulatory, or go-to-market costs.
This Integration Strengthens EUDA's Ecosystem By Enabling:​​​
Greater user engagement through digital utilities
Enhanced transparency through on-chain verification​
A compliant alternative to traditional rewards mechanisms
Technological modernization without engaging in token issuance or speculation
QB Will Increase Momentum Across EUDA's Four Flagship Growth Drivers
Euda Helixe Nutragenic Supplement
Euda Helixe is a next-generation immune health formula that modulates gene expression by activating beneficial genes while silencing harmful ones, leveraging cutting-edge epigenetic science. Management projects  500,000 bottles sold in the next 12 months, underscoring Euda Helixe’s potential as the cornerstone of EUDA’s precision-wellness portfolio.
​
EUDA Helixe 2.0 — EUDA’s flagship longevity nutraceutical has been reformulated with enhanced active ingredients and advanced delivery technology to improve potency, bioavailability, and global market appeal. With halal certification and optimized nutrient absorption, Helixe 2.0 is positioned to support cellular protection, skin health, metabolic resilience, and long-term vitality.
​​
Euda Bioenergy Capsules
Positioned as a non-invasive, full-body wellness system that brings together six complementary technologies in a single 50-minute session, the Bioenergy Capsule is designed to boost vitality, immunity, and cellular recovery through integrated light, frequency, thermal, and magnetic therapies. EUDA’s CK Health subsidiary aims to deploy  1,000+ capsules across Southeast Asia in 2025, creating a regional network that can deliver over 1 million treatment sessions annually. This hardware-as-wellness model provides recurring revenue while funnelling users toward EUDA’s higher-margin supplements and therapies.
​​
Stem-Cell Therapies & T-Cell Immunotherapy
Through commercial distribution agreements with Guangdong Cell Biotech, EUDA gains access to a repertoire of autologous stem-cell treatments already serviced by  37 treatment centers spanning China, Indonesia, and Cambodia. A subsequent deal with Shenzhen Inno Immune extends the portfolio to affordable T-cell immunotherapies retailing at USD8,000—a fraction of traditional costs—broadening their reach. These partnerships accelerate EUDA’s entry into regenerative medicine without heavy capex while positioning the company as a one-stop longevity platform.
​
In December 2025, EUDA launched a comprehensive stem cell therapy platform and opened its first longevity clinic in Shenzhen, China as part of accelerating its regenerative medicine strategy. EUDA also announced a nationwide stem cell extraction, processing, cryogenic storage, logistics, and clinical delivery platform in China with strategic partners Shenzhen Inno Immune and Wuhan Kaien Hospital.
​​
CRISPR Gene Editing Platform
EUDA frames CRISPR not as another therapy but as a “genetic operating system” capable of precisely cutting out what no longer serves you and enhancing what does. The program targets aging-related genes to strengthen immunity, improve detox pathways, and mitigate inherited disease risks. By integrating CRISPR with its nutraceuticals and cell therapies, EUDA envisions a closed-loop longevity ecosystem—from molecular maintenance to cellular rejuvenation (stem cells) and finally DNA-level optimization (CRISPR)—unlocking multiple monetization tiers as regulatory frameworks evolve
Recent Milestones Building Real Momentum
EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant
Announced on 4 March 2026, EUDA Health Holdings Limited disclosed the full repurchase and cancellation of its existing warrant agreement with Streeterville Capital. The warrant, originally issued under a securities purchase agreement dated 26 November 2025 and subsequently amended on 16 December 2025 and 13 January 2026, had been exercisable into up to 2,000,000 newly issued ordinary shares. On 27 February 2026, the Company repurchased the warrant in full for US$125,000, following which it was cancelled and declared no longer outstanding. As a result of this transaction, no warrants remain under the agreement and the potential dilutive share issuance has been fully eliminated. By retiring this instrument, EUDA aims to simplify its capital structure and remove outstanding equity overhang, supporting a cleaner financial position as it continues to pursue its broader growth strategy in non-invasive and longevity-focused healthcare across Asia.
EUDA Health Announces Second Amendment to Streeterville Warrant Agreement
Announced on 15 January 2026, EUDA Health Holdings Limited disclosed a second amendment to its existing warrant agreement with Streeterville Capital, further refining the terms of the previously issued equity-linked financing instrument. The amendment reduces the warrant exercise price from US$4.00 to US$2.00 per share and lowers the minimum share price threshold required to trigger a forced exercise from US$6.00 to US$3.00, while leaving all other warrant provisions unchanged. By adjusting these terms, EUDA aims to align the warrant with prevailing market conditions and preserve flexibility in its capital structure, while remaining focused on executing its business plan across preventive health, longevity solutions, and personalised healthcare across Asia.
EUDA isn’t just announcing bold ideas—it’s executing a roll-up strategy that will change the landscape for non-invasive healthcare across Southeast Asia.
Investment Thesis in One Sentence
Even a small foothold in Asia’s surging longevity market could dramatically revalue EUDA, especially as the QB-enabled digital rewards ecosystem deepens customer engagement and accelerates platform-wide growth.
Latest
News
04 MAR 2026
EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant
SINGAPORE, March 04, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has repurchased and cancelled in full the warrant previously issued to Streeterville Capital, LLC.
SINGAPORE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has entered into a second amendment to its previously disclosed warrant agreement with Streeterville Capital, LLC.
13 JAN 2026
EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform
SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that its wholly owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutics and customised medicines for a wide range of diseases in China.
Seasoned Leadership Steering the Longevity Vision
EUDA’s executive bench blends decades of life-sciences expertise with hard-nosed operational know-how—an essential mix for scaling a multi-faceted wellness platform.
EUDA’s leadership combines deal velocity, scientific rigor, and financial discipline—the very attributes that can turn a diversified longevity toolkit into a dominant regional franchise.